- Home
- MLYS vs DNTH Comparison
MLYS vs DNTH Comparison
Compare MLYS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- DNTH
- Stock Information
- Founded
- MLYS 2019
- DNTH 2015
- Country
- MLYS United States
- DNTH United States
- Employees
- MLYS N/A
- DNTH N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- DNTH Health Care
- Exchange
- MLYS Nasdaq
- DNTH Nasdaq
- Market Cap
- MLYS 609.7M
- DNTH 711.2M
- IPO Year
- MLYS 2023
- DNTH N/A
- Fundamental
- Price
- MLYS $12.34
- DNTH $23.80
- Analyst Decision
- MLYS Strong Buy
- DNTH Strong Buy
- Analyst Count
- MLYS 2
- DNTH 9
- Target Price
- MLYS $30.00
- DNTH $46.43
- AVG Volume (30 Days)
- MLYS 163.5K
- DNTH 203.7K
- Earning Date
- MLYS 11-11-2024
- DNTH 11-07-2024
- Dividend Yield
- MLYS N/A
- DNTH N/A
- EPS Growth
- MLYS N/A
- DNTH N/A
- EPS
- MLYS N/A
- DNTH N/A
- Revenue
- MLYS N/A
- DNTH $5,366,000.00
- Revenue This Year
- MLYS N/A
- DNTH $98.73
- Revenue Next Year
- MLYS N/A
- DNTH N/A
- P/E Ratio
- MLYS N/A
- DNTH N/A
- Revenue Growth
- MLYS N/A
- DNTH 51.41
- 52 Week Low
- MLYS $7.37
- DNTH $8.24
- 52 Week High
- MLYS $16.91
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- MLYS 47.76
- DNTH 46.14
- Support Level
- MLYS $11.19
- DNTH $22.59
- Resistance Level
- MLYS $12.57
- DNTH $24.57
- Average True Range (ATR)
- MLYS 0.80
- DNTH 1.49
- MACD
- MLYS -0.06
- DNTH 0.04
- Stochastic Oscillator
- MLYS 43.07
- DNTH 30.84
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.